HASSELT, Belgium, May 21, 2013 /PRNewswire/ --

Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present at BioEquity Europe 2013 in Stockholm, Sweden (May 22^nd-23^rd). Details of the presentation are listed below.

Dr Vaeck will highlight Complix' recent progress in applying its revolutionary Alphabody™ platform to generate novel therapeutics with first-in-class potential.

Alphabodies represent a transformative therapeutic development platform with the capacity to address a vast number of disease targets that are currently considered "undruggable" by the two main classes of therapeutic drugs: small chemical drugs and therapeutic antibodies. In particular, their ability to act on intracellular protein targets represents a major medical and commercial opportunity.

Complix has been developing Cell-Penetrating Alphabodies (CPABs), which have the unique capacity to enter cells effectively and modulate intracellular protein-to-protein interactions (PPIs). Most recently the Company´s research team has generated compelling data showing that CPABs, specific for an intracellular cancer target, are able to specifically interact with this target and cause significant biological effects on the cancer cells, in vitro as well as in vivo.

Dr Mark Vaeck, CEO of Complix, comments: "Our recently generated data on Alphabodies, particularly CPABs, show the promise of our Alphabody platform to transform drug development as we know it today. Alphabodies represent a unique therapeutic class. Unlike currently available biologics or small molecule drugs, Alphabodies have the potential to target a broad and validated but untouched target universe of proteins that are located inside cells. The unprecedented versatility, stability and cell penetrating capacity of Alphabodies enables them to target these intracellular PPIs, which are known to play a key role in the initiation and progression of major diseases such as cancer, autoimmunity, CNS and metabolic diseases. We are confident that our Alphabody platform can create next-generation therapeutics that will make a real difference in the treatment of disease and ultimately to the life of patients."

Details of the presentation are as follows:

Title: Complix NV
Time: Wednesday May 22^nd, 2013 at 3.30-3.55pm CET
Location: Drottingholmsalen A
Venue: Sheraton Stockholm Hotel

About Complix

Complix is a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, mainly focused on oncology and autoimmunity/inflammation. Alphabodies are a revolutionary class of protein therapeutics that combine attractive features from antibodies, like high target specificity and affinity, with benefits from small chemicals like extreme stability and cell penetration capacity. Alphabodies are small, single-chain proteins, with a triple-stranded alpha-helical coil structure, designed by computer modeling, but inspired by naturally existing protein motifs. Thanks to their unique features, Alphabodies can address a wide range of disease targets, both intracellular and extracellular, that are considered undruggable by conventional small chemicals or biologics.

Complix has established a strong intellectual property position protecting the Alphabody™ platform and its emerging product portfolio through the filing of multiple broad patent applications. Alphabody-based therapeutics are independent of antibody-based patent claims and offer a unique freedom-to-operate position.

The Company has raised close to €14 million in funding (approximately US$18 million), including a €7 million Series A equity round in 2010 with Vesalius Biocapital, LRM and Omnes Capital as main investors.

Complix is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg. The Company has a fully owned subsidiary in Luxembourg and has established research alliances with CRP-Santé (Luxembourg) and VIB (Belgium). For further information, please visit http://www.complix.com.

Contacts

Complix NV
Dr. Mark Vaeck, CEO
+32-9-261-69-40

SOURCE Complix